| Through new drug launches, panel discussions, and similar forums. | 患者擁護
> 薬物および関連治療 | 規制上のパートナーシップ
> 規制機関との連携 | 1,000 | Regional | Sometimes | 115028447628 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | がん
> がん：ほとんどの種類 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 10,000 | National | Regularly | 114998266569 |
| We assess cost-effectiveness. | 肝臓
> 肝疾患：ほとんどの種類 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100,000 | National | Sometimes | 114998327089 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 全般的な健康状態
> 医療提供 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100,000 | National | Regularly | 115009387424 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | がん
> がん：ほとんどの種類 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 10,000 | National | Regularly | 114998266569 |
| Attendance at relevant committee meetings and informal consultative sessions. | 先天性
> 先天性：心臓 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 10,000 | National | Rarely | 115003445044 |
| Activities include policy forums, stakeholder consultations, meetings with relevant government ministries, and related engagements. | レア
> 希少疾患：ほとんどの種類 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 1,000 | National | Regularly | 115033450975 |
| Convening public hearings in the National Assembly and submitting formal recommendations to the Ministry of Health and Welfare [in Korea]. | メンタルヘルス
> メンタルヘルス：ほとんどの状態 | 政策と法律への影響
> 医療政策と法律に影響を与える | 5,000 | Regional | Sometimes | 115019561629 |
| Activities included participation in policy forums advocating for the reimbursement of treatments currently excluded from public health insurance coverage, including Durvalumab and the graft-versus-host disease treatment Belumosudil. | がん
> がん：血液 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 100,000 | Regional | Sometimes | 115008918207 |
| Convening of National Assembly public hearings. | メンタルヘルス
> メンタルヘルス：ほとんどの状態 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 5,000 | Regional | Sometimes | 115019561629 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | がん
> がん：血液 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 1,000 | Regional | Sometimes | 115028455157 |
| Activities include participation in forums and debates, submission of petitions to the 인권위 [국가인권위원회 – National Human Rights Commission]. | 患者擁護
> 患者の権利 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 5,000 | Regional | Regularly | 115033350867 |
| Participated in a National Assembly policy forum on medicines not covered by public health insurance to convey the patient perspective. | がん
> がん：乳房 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 5,000 | National | Sometimes | 115058944486 |
| A request for the re-listing of a Parkinson's disease treatment. | 神経変性
> パーキンソン病 | 政策と法律への影響
> 医療における障壁・異常への対処 | 5,000 | National | Rarely | 115055431165 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | がん
> がん：ほとんどの種類 | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | 10,000 | National | Regularly | 114998266569 |
| Participated in a National Assembly policy debate on non-reimbursable drugs to convey patients' voices, and engaged in a petition drive to advocate for reimbursement coverage. | がん
> がん：乳房 | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | 5,000 | National | Sometimes | 115058944486 |
| We assess cost-effectiveness. | 肝臓
> 肝疾患：ほとんどの種類 | 価格設定と手頃な価格の擁護
> 価格審査委員会の交渉に参加する | 100,000 | National | Sometimes | 114998327089 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | がん
> がん：血液 | 価格設定と手頃な価格の擁護
> 価格審査委員会の交渉に参加する | 1,000 | Regional | Sometimes | 115028455157 |
| Reimbursement rates for basic welfare recipients. | メンタルヘルス
> メンタルヘルス：ほとんどの状態 | 価格設定と手頃な価格の擁護
> 低所得者や脆弱な立場にある人々のコスト面での障壁に対処する | 5,000 | Regional | Sometimes | 115021952415 |
| Inclusion of medical devices — such as continuous glucose monitors and insulin pumps — on the national health insurance formulary. | 内分泌
> 糖尿病：1型 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 100,000 | National | No | 114998267322 |
| Activities included participation in policy forums advocating for the reimbursement of treatments currently excluded from public health insurance coverage, including Durvalumab [help the body's immune system recognize and destroy cancer] and the graft-versus-host disease treatment Belumosudil. | がん
> がん：血液 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 100,000 | Regional | Sometimes | 115008918207 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | がん
> がん：血液 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 1,000 | Regional | Sometimes | 115028455157 |
| Participated in a National Assembly policy debate on non-reimbursable drugs to convey patients' voices, and engaged in a petition drive to advocate for reimbursement coverage. | がん
> がん：乳房 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 5,000 | National | Sometimes | 115058944486 |
| A request for the re-listing of a Parkinson's disease treatment. | 神経変性
> パーキンソン病 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 5,000 | National | Rarely | 115055431165 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 全般的な健康状態
> 医療提供 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | 100,000 | National | Regularly | 115009387424 |
| We submit written recommendations on a regular basis. | がん
> がん：血液 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | 10,000 | National | Regularly | 115056090120 |
| Participated in a National Assembly policy forum on medicines not covered by public health insurance to convey the patient perspective. | がん
> がん：乳房 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | 5,000 | National | Sometimes | 115058944486 |
| We submit written recommendations on a regular basis. | がん
> がん：血液 | エビデンスに基づく患者の意見
> エビデンスとインサイトを政策インプットに変換する | 10,000 | National | Regularly | 115056090120 |
| Attendance at relevant committee meetings and informal consultative sessions. | 先天性
> 先天性：心臓 | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 10,000 | National | Rarely | 115003445044 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 全般的な健康状態
> 医療提供 | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 100,000 | National | Regularly | 115009387424 |
| Activities include participation in forums and debates, submission of petitions to the 인권위 [국가인권위원회 – National Human Rights Commission]. | 患者擁護
> 患者の権利 | 患者の権利の擁護/生活の質の向上
> 患者体験の保護・改善 | 5,000 | Regional | Regularly | 115033350867 |
インタラクション
アクションと支援活動
7 メンション
